petri-dish-lid-and-hand
1 May 2010Biotech

What next for stem cell research?

When, in the course of case G2/06 (the WARF application), the Enlarged Board of Appeal of the European Patent Office (EPO) was invited to seek the assistance of the Court of Justice (the court) in construing Article 6 of the Biotechnology Directive, it must have come as no surprise to observers that it declined this invitation. The enlarged board was not persuaded by the potential awkwardness of the court subsequently reaching an alternative view as to the patentability of embryonic stem cell lines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
17 November 2026   A US judge tosses an antitrust lawsuit accusing Alexion of using sham patent litigation to delay competition to Soliris, finding that its favourable settlement with a rival undermined the claims.
Biotech
16 November 2026   The Swiss pharma giant will work with a Taiwan-based biotech’s ADC platform technologies to develop next-generation cancer therapies in a deal worth potentially more than $2bn, including $30m upfront.
Biotech
13 November 2026   Curiox claims confidential information shared during talks about a potential business partnership was used to develop a competing cell preparation system within months, despite the South Korean company spending years developing its own technology.